Search Results - Pascal Claudepierre
- Showing 1 - 9 results of 9
-
1
Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health ins... by Pascal Claudepierre, Laura Pina Vegas, Emilie Sbidian, Siham Iggui
Published in RMD Open (2024-08-01)Get full text
Article -
2
Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance databas... by Pascal Claudepierre, Léa Bastard, Lea Hoisnard, Laura Pina Vegas, Emilie Sbidian
Published in RMD Open (2022-11-01)Get full text
Article -
3
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (... by Pascal Claudepierre, Léa Bastard, Laura Pina Vegas, Emilie Sbidian, Laetitia Penso
Published in RMD Open (2024-02-01)Get full text
Article -
4
5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort by Sofia Ramiro, Désirée van der Heijde, Maxime Dougados, Anna Molto, Pascal Claudepierre, Alexandre Sepriano, Floris A van Gaalen, Queeny Madari, Daniel Wendling
Published in RMD Open (2020-02-01)Get full text
Article -
5
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospectiv... by Maxime Dougados, Pascal Claudepierre, Philippe Goupille, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas, Adeline Ryussen-Witrand, Emilie Desfleurs, Audrey Lardy-Cleaud
Published in RMD Open (2024-02-01)Get full text
Article -
6
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort by Francis Berenbaum, Maxime Dougados, Laure Gossec, Anna Molto, Pascal Claudepierre, Adeline Ruyssen-Witrand, Bernard Combe, Alain Saraux, Chris Serrand, Daniel Wendling, Sandrine Alonso
Published in RMD Open (2024-09-01)Get full text
Article -
7
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database by Léa Hoisnard, Bénédicte Lebrun-Vignes, Sébastien Maury, Matthieu Mahevas, Khalil El Karoui, Lydia Roy, Anissa Zarour, Marc Michel, José L. Cohen, Aurélien Amiot, Pascal Claudepierre, Pierre Wolkenstein, Philippe Grimbert, Emilie Sbidian
Published in Scientific Reports (2022-05-01)Get full text
Article -
8
When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it? by Damien Loeuille, Pascal Claudepierre, Corinne Miceli-Richard, Renaud Felten, Emmanuelle Dernis, Hubert Marotte, Philippe Goupille, Athan Baillet, Anne Tournadre, Maxime Breban, Thierry Lequerre, Daniel Wendling, Cédric Lukas, Thao Pham, Félicie Costantino, Clément Prati, Adeline Ryussen-Witrand, Olivier Fakih, Frank Verhoeven, Laura Pina Vegas
Published in RMD Open (2025-07-01)Get full text
Article -
9
Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis: the ROC-SpA study, a randomised controlled study protocol by Jérémie Sellam, Laure Gossec, Pascal Claudepierre, Axel Finckh, Grégoire Cormier, Renaud Felten, Emmanuelle Dernis, Arnaud Constantin, Hubert Marotte, Philippe Goupille, Thierry Schaeverbeke, Athan Baillet, Anne Tournadre, Tristan Pascart, Maxime Breban, Valerie Devauchelle, Thierry Lequerre, Christian Jorgensen, Eric Lespessailles, Elisabeth Gervais, Daniel Wendling, Cédric Lukas, Corinne Miceli, Emilie Presles, Stephan Pavy, Jean-Hugues Salmon, Christian Marcelli, Olivier Brocq, Beatrice Bouvard, Benoit Le Goff, Florence Rancon, Theodora Bejan-Angoulvant, Elisa Dalix, Madjid Akrour, Liliane De Araujo, Christian H Roux
Published in BMJ Open (2024-09-01)Get full text
Article
